reports
QuickView: Eye-D and CellDetect bladder reach milestones
Two of BioLight’s important assets have recently achieved milestones. Eye-D has begun a Phase I/IIa US trial in glaucoma and a patent protecting the drug-delivery platform until 2031 has been issued. The potential of CellDetect to improve the detection of bladder cancer using cytology has been supported by interim data from a 65-patient, blinded clinical trial. Despite these advances and BioLight’s broad pipeline, its market cap is only NIS79m.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.